Merck & Company
2000 Galloping Hill Road
About Merck & Company
Merck and Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Merck discovers, develops, manufactures, and markets vaccines and medicines in over 20 therapeutic categories directly and through its joint ventures. Our mission is to provide society with superior products and services by developing innovations and solutions that improve the quality of life. The focus of research at Merck is on innovation in all areas of drug research and development, working on programs to satisfy unmet medical needs.
With approximately 60,000 employees, Merck conducts research at ten major research centers in the United States, Europe, and Japan, manufactures products in 30 facilities, and sells products in approximately 150 countries.
At Merck, our strategy for growth is based on breakthrough research - both internal and external through partnerships - and demonstrating the value of our medicines to patients, payers, and providers. Worldwide sales in 2004 were $22.9 billion. Merck continues to invest heavily in research and development, with R&D spending in 2005 estimated to be approximately $4 billion.
Merck's product line includes a broad portfolio of highly innovative prescription products in important therapeutic areas. Human health products include medicines to treat high blood pressure, congestive heart failure, elevated cholesterol levels, osteoporosis, benign prostatic hypertrophy, arthritis, pain, migraine, glaucoma, gastrointestinal ulcers, infectious diseases (antibiotic, anti-fungal, and antiviral agents), and vaccines to prevent childhood diseases and hepatitis A and B.
At Merck, we are strongly committed to partnership success. We have a long tradition of successful partnerships. Alliances with innovative partners are an integral part of our long-term business and research strategy. More than one-third of our sales are from alliance products and patents, including some of our biggest growth drivers.
Our vision is to create a "virtual lab" - the pursuit of the best scientific programs from both internal research and external collaborations. This approach will accelerate the successful development and commercialization of breakthrough discoveries that can bring meaningful improvements to patients' lives.
Our focus is seeking alliances for new NCE's and biological entities as product candidates for development. We are open to basic research collaborations and early research technologies as well.
Merck welcomes partnerships touching virtually all human health therapeutic areas that address unmet needs for patients, as well as technologies that will enhance the productivity of our research laboratories. Therapeutic areas of particular interest include cancer, central nervous system disorders, diabetes, and obesity. Also of interest include the following: anti-infectives, anti-virals, cardiovascular diseases, gastrointestinal diseases, immunology, new vaccine technology, ophthalmics, osteoporosis, pain, respiratory, vaccines, and platform research technology.
To contact Merck about a licensing opportunity, please contact Chief Licensing Officer, Merck & Co., Inc., One Merck Drive, P.O. Box 100, Whitehouse Station, NJ 08889 USA; Fax: 908-735-1201. Please provide a brief, non-confidential overview of your discovery with sufficient data to allow a preliminary scientific review.
For further information, please visit our website at http://www.merck.com/licensing/
2793 articles with Merck & Company
Merck announced today that Robert M. Davis, chief financial offer and executive vice president, Merck Global Services, is scheduled to present at Citi’s 2018 Global Healthcare Conference in New York on Dec. 5, 2018 at 8:45 a.m. EST.
Noting that from 1998 to 2017 there have been about 146 failed shots at developing drugs for Alzheimer’s disease, PhRMA released a report on the state of the industry. This would not lead most people to think there are many reasons to be optimistic about Alzheimer’s disease research, but the repo...
Back in August, China’s Center for Drug Evaluation, its version of the U.S. Food and Drug Administration (FDA), fast-tracked 48 drugs that had already been approved in the U.S., Japan or Europe. These approvals reflect changes to China’s drug pharmaceutical environment.
According to the American Cancer Society, almost 601,000 people in the U.S. died of cancer in 2017. The two most common types of cancer are lung cancer and breast cancer, followed by colorectal cancer, prostate cancer and stomach cancer.
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Compared to Chemotherapy in Patients with Advanced Esophageal or Esophagogastric Junction Carcinoma Whose Tumors Express PD-L1 (CPS ≥10)
With Pivotal KEYNOTE-181 Trial Meeting Primary Endpoint of OS, KEYTRUDA Becomes the First Anti-PD-1 Therapy to Demonstrate a Survival Benefit for These Patients
11/14/2018The fund will be administered through the Ventura County Community Foundation. Officials indicate that 100 percent of the funds will go to help victims’ families. The Foundation is calling for additional donations.
Merck Begins Rolling Submission of Licensure Application for V920 (rVSV∆G-ZEBOV-GP) to U.S. Food and Drug Administration
V920 is the Company’s Investigational Vaccine for Ebola Zaire
As a private company, Moderna has amassed a significant fortune of billions of dollars and a valuation of about $7 billion – all of this without any marketed product in the company’s field of messenger RNA (mRNA).
On Friday, the FDA approved Merck's Keytruda, an anti-PD-1 therapy, for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with the chemotherapy drug sorafenib.
11/12/2018As an outbreak of the Ebola virus in the Democratic Republic of the Congo worsens, a team of health officials has taken four experimental vaccines to the front lines and begun to administer it to patients who may have been exposed to the deadly virus.
Cabaletta Bio launched out of the University of Pennsylvania with an exclusive license deal and two multi-year sponsored research agreements. The fledgling biotech company will work on engineered T cell products for B cell-mediated autoimmune disease.
New Data from Investigational Study of LENVIMA® (lenvatinib) and KEYTRUDA® (pembrolizumab) Combination in Three Different Tumor Types Presented at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting
First presentation of LENVIMA and KEYTRUDA combination data in patients with metastatic non-small cell lung cancer, metastatic melanoma and metastatic urothelial carcinoma from Study 111/KEYNOTE-146
Plenty of biotech companies will be releasing their third-quarter financial reports next week. Let’s take a quick look at some of these companies and their top stories they reported through 3Q2018.
Care2 Petition Calls On Pharmaceutical Giant Merck Not To Endanger The Lives Of Millions Of Children
The Company Announced Its Decision To End Its Long-Term Agreement To Provide The Rotavirus Vaccinee To Children In West Africa In Favor Of Shifting To China Where They Could Increase Profit Margins
Indianapolis-based Eli Lilly pulled another BACE therapy from its pipeline, the company announced in a third-quarter conference call.
Early Phase 1 Data from Merck’s Oncology Pipeline for Investigational Anti-LAG-3 Therapy (MK-4280) and Anti-TIGIT Therapy (MK-7684) to Be Presented at SITC’s 33rd Annual Meeting
With New Data, Merck Now has Presented Early Clinical Data for Six Investigational Oncology Pipeline Candidates Spanning Several Pathways
Merck Halts Supply of Lifesaving Vaccine for African Kids to Seek Greater Profits in China, US, Says AHF
AHF condemns Merck for cutting off lifesaving vaccine for children dying from diarrhea in Africa while it also announces plans to expand distribution—and far more lucrative sales—in China
Although there is some slowdown as the FDA moves into the holiday season in late November and into December, there are still upcoming target action dates. Here’s a look at this week’s PDUFA dates.
To suggest that the pharma industry is a reluctant partner in President Donald Trump’s attempts to decrease drug prices is to overstate the fact. But now the industry appears to be pushing back, at least a little bit.
Merck’s blockbuster anti-PD-1 therapy Keytruda has snagged another regulatory approval from the U.S. Food and Drug Administration. The checkpoint inhibitor has been approved, in combination with chemotherapy, as a first-line treatment for patients with metastatic squamous non-small cell lung cancer.